ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells
- 14 August 2014
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 124 (7), 1070-1080
- https://doi.org/10.1182/blood-2013-10-535245
Abstract
Key Points ICOS-based CARs program bipolar TH17/TH1 cells with augmented effector function and in vivo persistence. The expression of selected CAR endodomains can program T cells for their subsequent differentiation fates and effector functions.This publication has 41 references indexed in Scilit:
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaThe New England Journal of Medicine, 2013
- A Validated Regulatory Network for Th17 Cell SpecificationCell, 2012
- Th17 Cells Are Long Lived and Retain a Stem Cell-like Molecular SignatureImmunity, 2011
- A human memory T cell subset with stem cell–like propertiesNature Medicine, 2011
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid LeukemiaThe New England Journal of Medicine, 2011
- CD28 Costimulation Impairs the Efficacy of a Redirected T-cell Antitumor Attack in the Presence of Regulatory T cells Which Can Be Overcome by Preventing Lck ActivationMolecular Therapy, 2011
- Adoptively transferred effector cells derived from naïve rather than central memory CD8 + T cells mediate superior antitumor immunityProceedings of the National Academy of Sciences of the United States of America, 2009
- Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domainsProceedings of the National Academy of Sciences of the United States of America, 2009
- Anti-CTLA-4 therapy results in higher CD4 + ICOS hi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissuesProceedings of the National Academy of Sciences of the United States of America, 2009
- Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastomaNature Medicine, 2008